Showing results (1071-1080 of 1,193) with videos related to
Sort By:
Pageof 120
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.Cancer|May 6, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapyJennifer Marvin-Peek, Courtney D DiNardo, Sanam Loghavi, et al.American Journal of Hematology|September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatmentCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaKiyomi Morita, Hagop M Kantarjian, Feng Wang, et al.Blood|September 7, 2018
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Juliana E Hidalgo-Lopez, et al.Journal of Hematology & Oncology|October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLMusa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.American Journal of Hematology|February 8, 2025
Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary TherapiesJayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, et al.American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.Journal for Immunotherapy of Cancer|February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantationChantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.Pageof 120